Vyome announces Nasdaq approval of merger with ReShape Lifesciences

Written by Emily J. Thompson, Senior Investment Analyst

RSLS%

Updated: Aug 13 2025

0mins

Merger and Listing Approval: Vyome Therapeutics has received approval from The Nasdaq Stock Market for its listing following the merger with ReShape Lifesciences, set to take effect on August 15 under the name Vyome Holdings, Inc. and trading symbol "HIND."
Focus on Shareholder Value: Chairman Krishna Gupta emphasized the company's commitment to shareholder value and innovation in the healthcare market, inviting RSLS shareholders and others to join their journey.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Vyome announces Nasdaq approval of merger with ReShape Lifesciences

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Meta Platforms' $10 Billion AI Strategy for 2026

Federal Realty (FRT) Achieves 58 Years of Dividend Increases with 4.4% Yield

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch